Guido Marcucci MD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Chief, Division of Leukemia; Chair and Professor, Department of Hematologic Malignancies Translational Science; Director, Gehr Family Center for Leukemia Research City of Hope Comprehensive Cancer Center

Join to view full profile

Division of Leukemia1500 East Duarte RoadDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-389-3061

Dr. Marcucci is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Marcucci's full profile Already have an account?

Summary

Dr. Guido Marcucci is Medical Oncologist is affiliated with City of Hope's Helford Clinical Research Hospital. He is Chief of the Division of Leukemia, Chair and Professor of the Dept. of Hematologic Malignancies Translational Science, Director of the Gehr Family Center for Leukemia Research, and Director of the Hematopoietic Tissue Biorepository. He is experienced in hematologic oncology, leukemia, hematopoietic stem cell transplantation, flow cytometry, cytogenetics, and drug delivery systems.

Education & Training

UPMC Medical EducationResidency, Gastroenterology, 2019 - 2025
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1997 - 1998
University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1997
SUNY at Buffalo Graduate Medical-Dental Education Consortium (Millard Fillmore)Residency, Internal Medicine, 1990 - 1993
University of Cattolica del Sacro CuoreClass of 1987

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2015 - 2026
OH State Medical License 1997 - 2016
NY State Medical License 1995 - 1998
PA State Medical License 1993 - 1996
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification Sunrise Acute Care, Allscripts, 2016-2017

Clinical Trials

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
COMPLETED
PHASE1
FR901228 in Treating Patients With Hematologic Cancer
COMPLETED
PHASE1
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
COMPLETED
PHASE1

Publications & Presentations

PubMed

Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia.
Anil Kumar, Kory Hamane, Caroline Duault, Joao Rodrigues Lima-Junior, Da Hae Jung
Cell Reports. Medicine. 2026-08-18
Allogeneic heamatopoietic stem cell transplant in patients with refractory T-cell large granular lymphocytic leukaemia: A single-centre experience.
Paolo Lopedote, Lauren Epler-Tagliaferro, Matthew G Mei, Sunmin Park, Annie Xiao
British Journal of Haematology. 2026-08-12
Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.
Diana T Samuels, Brian J Ball, Ni-Chun Tsai, Salman Otoukesh, Shukaib Arslan
Blood Neoplasia. 2026-08-01

Journal Articles

Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia
Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature

Abstracts/Posters

Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug ResistanceClinically Relevant Abstract
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in AdultsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017

Press Mentions

Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDSDecember 12th, 2022
myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients Than Physician Prescribed TreatmentDecember 14th, 2021
myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients Than Physician Prescribed TreatmentDecember 14th, 2021

Grant Support

State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapyBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2024–2029
Targeting Immune Escape in CML/MPN TransformationBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2023–2028
Targeting MicroRNAs to Eradicate Leukemia Stem CellsBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2017–2027
Targeting MicroRNAs to Eradicate Leukemia Stem CellsBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2017–2027
Targeting MicroRNAs to Eradicate Leukemia Stem CellsBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2017–2027